Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report
Mona Passler, Jalid Sehouli, Klaus Pietzner, Department of Gynecology, Competence Center for Ovarian Cancer (EKZE), Charité - University Medicine, Berlin 13353, Germany
Eliane T Taube, Institute of Pathology, Charité University Hospital, Berlin 10117, Germany
Author contributions: Passler M reviewed the literature, contributed to manuscript drafting and was responsible for the submission process; Eliane T Taube was responsible for the pathological findings and review of the literature; Sehouli J and Pietzner K were the attending doctors and responsible for important intellectual content.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Mona Passler, Junior Researcher, Department of Gynecology, Competence Center for Ovarian Cancer (EKZE), Charité - University Medicine, Augustenburger Platz 1, Berlin 13353, Germany. firstname.lastname@example.org
Received: February 28, 2019
Peer-review started: March 4, 2019
First decision: April 11, 2019
Revised: July 8, 2019
Accepted: July 16, 2019
Article in press: July 17, 2019
Published online: July 24, 2019